OAM
ZNTL icon

Oppenheimer Asset Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Oppenheimer Asset Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,491
Closed -$253K – 1226
2022
Q1 		$253K Sell
5,491
-28
-0.5% -$1.51K ﹤0.01% 1066
2021
Q4 		$464K Buy
+5,519
New +$427K 0.01% 983

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

Oppenheimer Asset Management's ZNTL Position: Q2 2022 in Review

Oppenheimer Asset Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2022, closing a stake of 5,491 shares — an estimated $253K sold.

Oppenheimer Asset Management first reported a position in ZNTL in Q4 2021 and held it in 2 quarters. The position peaked at $464K in Q4 2021. 122 funds tracked by Wall St. Rank hold ZNTL as of Q2 2022.

  • Oppenheimer Asset Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Oppenheimer Asset Management sold 5,491 Zentalis Pharmaceuticals shares in Q2 2022, an estimated $253K.
  • Oppenheimer Asset Management first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Oppenheimer Asset Management's Zentalis Pharmaceuticals position peaked at $464K in Q4 2021.
  • 122 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2022.

Based on Oppenheimer Asset Management's 13F filing for Q2 2022, filed 8 Aug 2022.